Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: Study protocol for an open-label randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Mansoor, Leila E ^a   Abdool Karim, Quarraisha ^a,b   Mngadi, Kathryn T ^a   Dlamini, Sarah ^a   Montague, Carl ^a   Nkomonde, Nelisiwe ^a   Mvandaba, Nomzamo ^a   Baxter, Cheryl ^a   Gengiah, Tanuja N ^a   Samsunder, Natasha ^a   Dawood, Halima ^a   Grobler, Anneke ^a   Frohlich, Janet A ^a   Abdool Karim, Salim S ^a,b,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Department of Medicine   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Health systems strengthening; HIV prevention; Implementation; Microbicide; South Africa; Tenofovir gel

Indexed keywords

TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GEL; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FAMILY PLANNING; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AFRICA; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; GEL; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH SERVICE; HIV INFECTIONS; METHODOLOGY; PROGRAM EVALUATION; RURAL HEALTH CARE; STANDARDS; TIME; TOTAL QUALITY MANAGEMENT; TRANSMISSION; TREATMENT OUTCOME; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CLINICAL PROTOCOLS; FAMILY PLANNING SERVICES; FEMALE; GELS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; PROGRAM EVALUATION; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; RESEARCH DESIGN; RURAL HEALTH SERVICES; SOUTH AFRICA; TENOFOVIR; TIME FACTORS; TREATMENT OUTCOME; URBAN HEALTH SERVICES; WOMEN'S HEALTH SERVICES; YOUNG ADULT;

EID: 84949133019     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-496     Document Type: Article

References (44)

1. UNAIDS, WHO: AIDS Epidemic Update. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2009.
2. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, Hlongwa-Madikizela L, Vermaak K, Padian NS: Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 2005, 19:1525-1534. 10.1097/01.aids.0000183129.16830.06.
3. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, Mbelle N, Van Zyl J, Parker W, Zungu NP, Pezi S: South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A Turning Tide Among Teenagers?. Cape Town: HSRC Press; 2009.
4. Haynes BF, Shattock RJ: Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 2008, 122:3-9. 10.1016/j.jaci.2008.03.036.
5. Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, Wira CR, Fanger MW, Howell AL: Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology 2004, 113:524-533. 10.1111/j.1365-2567.2004.01990.x.
6. Shattock RJ, Moore JP: Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003, 1:25-34. 10.1038/nrmicro729.
7. Abdool Karim Q: Heterosexual transmission of HIV - the importance of a gendered perspective in HIV prevention. In HIV/AIDS in South Africa. Edited by: Abdool Karim SS, Abdool Karim Q. Cape Town: Cambridge University Press; 2005:243-461.
8. Gregson S, Nyamukapa CA, Garnett GP, Mason PR, Zhuwau T, Carael M, Chandiwana SK, Anderson RM: Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. Lancet 2002, 359:1896-1903. 10.1016/S0140-6736(02)08780-9.
9. Abdool Karim Q, Abdool Karim SS, Nkomokazi J: Sexual behaviour and knowledge of AIDS among urban black mothers. Implications for AIDS intervention programmes. S Afr Med J 1991, 80:340-343.
10. Simbayi LC, Chauveau J, Shisana O: Behavioural responses of South African youth to the HIV/AIDS epidemic: a nationwide survey. AIDS Care 2004, 16:605-618. 10.1080/09540120410001716405.
11. Hoffman S, O'Sullivan LF, Harrison A, Dolezal C, Monroe-Wise A: HIV risk behaviors and the context of sexual coercion in young adults' sexual interactions: results from a diary study in rural South Africa. Sex Transm Dis 2006, 33:52-58. 10.1097/01.olq.0000187198.77612.d8.
12. Jewkes RK, Levin JB, Penn-Kekana LA: Gender inequalities, intimate partner violence and HIV preventive practices: findings of a South African cross-sectional study. Soc Sci Med 2003, 56:125-134. 10.1016/S0277-9536(02)00012-6.
13. Gupta GR, Weiss E, Whelan D: Male-female inequalities result in submission to high-risk sex in many societies. Special report: women and HIV. AIDS Anal Afr 1995, 5:8-9.
14. Stein ZA: HIV prevention: the need for methods women can use. Am J Public Health 1990, 80:460-462. 10.2105/AJPH.80.4.460.
15. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008, 3:e1474. 10.1371/journal.pone.0001474.
16. Richardson BA, Lavreys L, Martin HL Jr, Stevens CE, Ngugi E, Mandaliya K, Bwayo J, Ndinya-Achola J, Kreiss JK: Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 2001, 28:394-400. 10.1097/00007435-200107000-00006.
17. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG: Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA 2002, 287:1117-1122.
18. van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Abdool Karim SS, Mâsse B, Perriëns J, Laga M, COL-1492 Study Group: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971-977. 10.1016/S0140-6736(02)11079-8.
19. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008, 359:463-472. 10.1056/NEJMoa0707957.
20. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1977-1987. 10.1016/S0140-6736(08)61842-5.
21. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J: PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376:1329-1337. 10.1016/S0140-6736(10)61086-0.
22. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Masse B, Hillier SL, Soto-Torres L: Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011, 25:957-966. 10.1097/QAD.0b013e32834541d9.
23. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, Anzala A, Holton D, Plummer F: Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992, 268:477-482. 10.1001/jama.1992.03490040053025.
24. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL: A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998, 339:504-510. 10.1056/NEJM199808203390803.
25. De Clercq E: Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 2007, 73:911-922. 10.1016/j.bcp.2006.09.014.
26. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS: In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010, 5:e9310. 10.1371/journal.pone.0009310.
27. Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Omar Z, Miya N, Mlisana K, Maarshalk S, Karim SS: Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther 2013,18(3):301-310.
28. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, on behalf of the CAPRISA 004 Trial Group: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174. 10.1126/science.1193748.
29. Abdool Karim Q, Abdool Karim SS, on behalf of the CAPRISA 004 Trial Group: CAPRISA 004: Effectiveness & Safety of Vaginal Microbicide 1% Tenofovir Gel for Prevention of HIV Infection in Women. Vienna, Austria: XVIII International AIDS Conference; 2010.
30. Williams BG, Abdool Karim SS, Gouws E, Abdool Karim Q: Potential Impact of Tenofovir Gel on the HIV Epidemic in South Africa. Vienna, Austria: XVIII International AIDS Conference; 2010.
31. Glynn JR, Biraro S, Weiss HA: Herpes simplex virus type 2: a key role in HIV incidence. AIDS 2009, 23:1595-1598. 10.1097/QAD.0b013e32832e15e8.
32. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D: Preexposure prophylaxis for HIV infection among African Women. N Engl J Med 2012, 367:411-422. 10.1056/NEJMoa1202614.
33. Marrazzo JRG, Nair G, Palanee T, Mkhize B, Nakabiito Taljaard M, Piper J, Gomez Feliciano K, Chirenje M: Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). In 20th CROI. Atlanta GA: Oral Abstract 26LB; 2013.
34. Richardson WC, Berwick DM, Bisgard JC: The Institute of Medicine report on medical errors. N Engl J Med 2000, 343:663-664. author reply 665.
35. Berwick DM: Disseminating innovations in health care. JAMA 2003, 289:1969-1975. 10.1001/jama.289.15.1969.
36. Berwick DM: Continuous improvement as an ideal in health care. N Engl J Med 1989, 320:53-56. 10.1056/NEJM198901053200110.
37. Abdool Karim Q, Kharsany AB, Frohlich JA, Werner L, Mashego M, Mlotshwa M, Madlala BT, Ntombela F, Abdool Karim SS: Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 2011, 40:922-930. 10.1093/ije/dyq176.
38. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580.
39. Schackman BR: Implementation science for the prevention and treatment of HIV/AIDS. J Acquir Immune Defic Syndr 2010,55(Suppl 1):S27-S31.
40. Kiggundu V, Watya S, Kigozi G, Serwadda D, Nalugoda F, Buwembo D, Settuba A, Anyokorit M, Nkale J, Kighoma N, Ssempijja V, Wawer M, Gray RH: The number of procedures required to achieve optimal competency with male circumcision: findings from a randomized trial in Rakai, Uganda. BJU Int 2009, 104:529-532. 10.1111/j.1464-410X.2009.08420.x.
41. Herman-Roloff A, Llewellyn E, Obiero W, Agot K, Ndinya-Achola J, Muraguri N, Bailey RC: Implementing voluntary medical male circumcision for HIV prevention in Nyanza Province, Kenya: lessons learned during the first year. PLoS One 2011, 6:e18299. 10.1371/journal.pone.0018299.
42. Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K, Giganti MJ, Welty TK, Chintu N, Chi BH, Wilfert CM, Shaffer N, Dabis F, Stringer JS, PEARL Study Team: Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA 2010, 304:293-302. 10.1001/jama.2010.990.
43. Mate KS, Bennett B, Mphatswe W, Barker P, Rollins N: Challenges for routine health system data management in a large public programme to prevent mother-to-child HIV transmission in South Africa. PLoS One 2009, 4:e5483. 10.1371/journal.pone.0005483.
44. Zong Z: Should post-trial provision of beneficial experimental interventions be mandatory in developing countries? J Med Ethics 2008, 34:188-192. 10.1136/jme.2006.018754.